Jim Pedicano

Learn More
BACKGROUND Lapaquistat acetate is a squalene synthase inhibitor investigated for the treatment of hypercholesterolemia. METHODS AND RESULTS This report summarizes the phase 2 and 3 results from the lapaquistat clinical program, which was halted at an advanced stage as a result of potential hepatic safety issues. Efficacy and safety data were pooled from(More)
PURPOSE This trial sought to determine, for the first time, the validity in human vaccinations of using two different recombinant vaccines in diversified prime-and-boost regimens to enhance T-cell responses to a tumor antigen. PATIENTS AND METHODS Eighteen patients with advanced tumors expressing carcinoembryonic antigen (CEA) were randomized to receive(More)
PURPOSE A phase I clinical trial in patients with advanced carcinoma was conducted, using a replication-defective avipox vaccine containing the gene for the human carcinoembryonic antigen (CEA). The canarypox vector, designated ALVAC, has the ability to infect human cells but cannot replicate. PATIENTS AND METHODS The recombinant vaccine, designated(More)
Eleven patients with malaria seen over five years in one emergency department demonstrate a trend toward more efficient diagnosis and outpatient treatment. Ten patients were diagnosed using a routine Wright's stained peripheral blood smear (three fortuitously). Because treatment of hospitalized patients consists of no more than oral chloroquine, the current(More)
Summary:Growth factors are routinely used after autotransplantation to accelerate hematopoietic recovery, and are continued until the absolute neutrophil count (ANC) is ⩾0.5 × 109/l on 3 consecutive days. Since ANC often increases to very high levels with this strategy, we discontinued growth factor on the first day ANC reached 0.5 × 109/l in 45 patients(More)
  • 1